Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate Patent Expiration

Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate is Used for treating HIV-1 infection in various patient populations, including those with no prior treatment history or virologically suppressed individuals. It was first introduced by Janssen Products Lp in its drug Symtuza on Jul 17, 2018.


Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate Patents

Given below is the list of patents protecting Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Symtuza US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent Oct 06, 2032 Janssen Prods
Symtuza US10786518 Compositions and methods of treating HIV Jul 19, 2038 Janssen Prods
Symtuza US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane Nov 04, 2020

(Expired)

Janssen Prods
Symtuza US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers Mar 09, 2021

(Expired)

Janssen Prods
Symtuza US7390791 Prodrugs of phosphonate nucleotide analogues Apr 17, 2025 Janssen Prods
Symtuza US7470506 Fitness assay and associated methods Jun 23, 2019

(Expired)

Janssen Prods
Symtuza US7700645 Pseudopolymorphic forms of a HIV protease inhibitor Dec 26, 2026 Janssen Prods
Symtuza US7803788 Prodrugs of phosphonate nucoleotide analogues Feb 02, 2022

(Expired)

Janssen Prods
Symtuza US8148374 Modulators of pharmacokinetic properties of therapeutics Sep 03, 2029 Janssen Prods
Symtuza US8518987 Pseudopolymorphic forms of a HIV protease inhibitor Feb 16, 2024

(Expired)

Janssen Prods
Symtuza US8597876 Method of treating HIV infection Jun 23, 2019

(Expired)

Janssen Prods
Symtuza US8754065 Tenofovir alafenamide hemifumarate Aug 15, 2032 Janssen Prods
Symtuza US9296769 Tenofovir alafenamide hemifumarate Aug 15, 2032 Janssen Prods
Symtuza US9889115 Fitness assay and associated methods Jun 23, 2019

(Expired)

Janssen Prods


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate's patents.

Given below is the list recent legal activities going on the following patents of Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate.

Event Date Patent/Publication
Patent litigations
Recordation of Patent Grant Mailed 29 Sep, 2020 US10786518
Patent Issue Date Used in PTA Calculation 29 Sep, 2020 US10786518
Email Notification 15 Sep, 2020 US10786518
Issue Notification Mailed 09 Sep, 2020 US10786518
Application Is Considered Ready for Issue 24 Aug, 2020 US10786518
Dispatch to FDC 24 Aug, 2020 US10786518
Issue Fee Payment Received 20 Aug, 2020 US10786518
Issue Fee Payment Verified 20 Aug, 2020 US10786518
Mailing Corrected Notice of Allowability 16 Jul, 2020 US10786518
Printer Rush- No mailing 16 Jul, 2020 US10786518



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳